Abstract Title: currently loading...

information currently loading...

close
Loading ... please wait
timer Loading ... please wait

Free Paper Session 9: Vascular Diseases Session

Date/Time: | Room:

Back to Previous

Title

Theme

14:30:00 M. Lukic United Kingdom Reallife anatomical and visual acuity outcomes in treatmentnaive patients treated with intravitreal aflibercept for diabetic macular oedema; 18 months results
14:36:00 m. Saleh France EVAPOR: Evaluation of Argon versus Pascal® laser efficacy on diabetic macular edema resorption
14:42:00 P. Schlottmann Argentina Predictors of early diabetic retinopathy improvement in patients with diabetic macular edema who received 3 or more monthly ranibizumab injections
14:48:00 R. Tadayoni France AntiVEGF/Anti–angiopoietin2 bispecific antibody RG7716 in diabetic macular edema: Key efficacy and safety results from the phase 2 BOULEVARD clinical trial
14:54:00 D. Eichenbaum United States AntiVEGF/Anti–angiopoietin2 bispecific antibody RG7716 in diabetic macular edema: Key secondary and exploratory outcomes in the phase 2 BOULEVARD clinical trial
15:00:00 J. Cardigos Portugal Choroid of diabetic patients without observed retinal vascular changes: A longitudinal study
15:06:00 I. Marques Portugal Characterization of the initial stages of diabetic retinal disease using OCT and OCTA
15:12:00 H. Al Hasid United Arab Emirates Prolonged oxygen support and retinopathy of prematurity (ROP) recurrence post intravitreal anti vascular endothelial growth factor (VEGF) injection in zone 1
15:18:00 U. Chakravarthy United Kingdom Does the duration of chronic diabetic oedema influence the effectiveness and safety outcomes achieved in patients treated with ILUVIEN (fluocinolone acetonide)? Clinical insights from the ILUVIEN registry safety study
15:24:00 T. Rodrigues Portugal Parafoveal capillary density changes in the early stages of diabetic retinopathy evaluated with OCTangiography
15:30:00 A. Santos Portugal Choroidal predictors for visual response to antiVEGF treatment in DME patients, using swept source OCT
15:36:00 R. Muni Canada Changes in aqueous cytokine levels following treatment with aflibercept in treatment naïve patients with diabetic macular edema
15:42:00 E. Durbant France Intravitreal triamcinolone injections in nonarteritic anterior ischemic optic neuropathy – 7 years followup
15:48:00 G. Adriono Indonesia Fenofibrate treatment in diabetic retinopathy with dyslipidemia: Effects on central macular thickness and macular volume, and serum endothelial nitric synthase, vascular cell adhesion molecule 1, and vascular endothelial growth factor levels
15:54:00 C. Bailey United Kingdom A national audit of UK electronic medical records (EMRs) to assess the safety and effectiveness of the ILUVIEN (fluocinolone acetonide) 190 micrograms intravitreal implant in patients with chronic diabetic macular oedema (DMO)

Want to find out more about EURETINA activities?

Contact us
© EURETINA All rights reserved